Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Diarrhea 3Prostatic Neoplasms 2Neoplasms 2Breast Neoplasms 2Vipoma 1Somatostatinoma 1Serotonin Syndrome 1Recurrence 1Rectal Neoplasms 1Pheochromocytoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphocele 1Intestinal Obstruction 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1Adenoma 1Acromegaly 1

Interventions

Irinotecan 58Bevacizumab 56Oxaliplatin 49Leucovorin 49Fluorouracil 49Capecitabine 45Cetuximab 44pembrolizumab 23IFL protocol 15Nivolumab 11regorafenib 10Panitumumab 10Celecoxib 8Radiotherapy 7Cyclophosphamide 7atezolizumab 6Surgical Procedures, Operative 6Gemcitabine 6Folfox protocol 6Colonoscopy 6trifluridine tipiracil drug combination 5Neoadjuvant Therapy 5Metformin 5Immunohistochemistry 5Biopsy 5tislelizumab 4spartalizumab 4durvalumab 4Trastuzumab 4Mitomycin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Colorectal Neoplasms × Octreotide × Clear all
NCT00006269 2012-05-25

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Novartis

Phase 3 Terminated
89 enrolled
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡